Cargando…
CLDN1 Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy
SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) treatment represents a major challenge in oncology. TNBC evolves into chemotherapy resistance for 60 to 70% of the patients. About 77% of the TNBC displays a lack of claudin-1 (CLDN1), a major tight junction component. We demonstrated that CLDN1 i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599637/ https://www.ncbi.nlm.nih.gov/pubmed/36291810 http://dx.doi.org/10.3390/cancers14205026 |